Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
09 2021
Historique:
received: 20 12 2020
revised: 28 07 2021
accepted: 29 07 2021
pubmed: 10 8 2021
medline: 15 12 2021
entrez: 9 8 2021
Statut: ppublish

Résumé

Although CAR-T cells are widely used to treat cancer, efficiency of CAR-T cell cytolytic responses has not been carefully examined. We engineered CAR specific for HMW-MAA (high-molecular-weight melanoma-associated antigen) and evaluated potency of CD8+ CAR-T cells to release cytolytic granules and to kill tissue-derived melanoma cells, which express different levels of HMW-MAA. CAR-T cells efficiently killed melanoma cells expressing high level of HMW-MAA, but not melanoma cells with lower levels of HMW-MAA. The same melanoma cells presenting significantly lower level of stimulatory peptide-MHC ligand were readily lysed by T cells transduced with genes encoding α,β-TCR specific for the peptide-MHC ligand. The data suggest that higher level of targeted molecules is required to engage a larger number of CARs than TCRs to induce efficient cytolytic granule release and destruction of melanoma cells. Understanding the difference in molecular mechanisms controlling activation thresholds of CAR- versus TCR-mediated responses will contribute to improving efficiency of CAR T cells required to eliminate solid tumors presenting low levels of targeted molecules.

Identifiants

pubmed: 34371020
pii: S0021-9258(21)00835-8
doi: 10.1016/j.jbc.2021.101033
pmc: PMC8452787
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0
HLA-A2 Antigen 0
HMW-MAA 0
Receptors, Antigen, T-Cell 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101033

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Nadia Anikeeva (N)

Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Sergey Panteleev (S)

Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Nicholas W Mazzanti (NW)

Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Mizue Terai (M)

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Takami Sato (T)

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Yuri Sykulev (Y)

Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address: Yuri.Sykulev@Jefferson.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH